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Abstract 
Background  Acute myocardial infarction (AMI) is a common cause of heart failure (HF), which can develop soon after AMI and 
may persist or resolve or develop late. HF after an MI is a major source of mortality. The cumulative incidence, prevalence and resolution of 
HF after MI in different age groups are poorly described. This study describes the natural history of HF after AMI according to age. Methods  
Patients with AMI during 1998 were identified from hospital records. HF was defined as treatment of symptoms and signs of HF with loop 
diuretics and was considered to have resolved if loop diuretic therapy could be stopped without recurrence of symptoms. Patients were cate-
gorised into those aged < 65 years, 65–75 years, and > 75 years. Results  Of 896 patients, 311, 297 and 288 were aged < 65, 65–75 and >75 
years and of whom 24%, 57% and 82% had died respectively by December 2005. Of these deaths, 24 (8%), 68 (23%) and 107 (37%) oc-
curred during the index admission, many associated with acute HF. A further 37 (12%), 63 (21%) and 82 (29%) developed HF that persisted 
until discharge, of whom 15, 44 and 62 subsequently died. After discharge, 53 (24%), 55 (40%) and 37 (47%) patients developed HF for the 
first time, of whom 26%, 62% and 76% subsequently died. Death was preceded by the development of HF in 35 (70%), 93 (91%) and 107 
(85%) in aged < 65 years, 65–75 years and >75 years, respectively. Conclusions  The risk of developing HF and of dying after an MI in-
creases progressively with age. Regardless of age, most deaths after a MI are preceded by the development of HF. 
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1  Introduction  
Heart failure (HF) is a common complication of myocar-
dial infarction (MI), which may develop early or late and 
persist, resolve or recur.[1] A growing proportion of patients 
with MI are aged > 65 years. Older patients are at greater 
risk of developing HF and have a poorer prognosis.[2–4] Sur-
prisingly, the complex pattern and timing of the develop-
ment and resolution of HF and the importance of such dis-
tinctions has not been quantified in relationship to age.[4,5] 
Understanding the drivers of morbidity and mortality after 
MI is important, given the great difference in mortality rates 
reported in clinical trials of MI compared to epidemiological 
studies. Improved understanding about which patients are at 
risk and the nature of the risk could help focus attention on 
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patients at greater need, to ensure that they receive appro-
priate therapy and that they are targeted for recruitment into 
clinical trials, which currently have rather low event rates. 
Treatment can only help patients who are at risk of compli-
cations that the treatment aims to prevent. 
2  Methods 
2.1  Study population 
Two hospitals in Hull and the East Riding of Yorkshire 
(UK) are sole providers of acute cardiac services for about 
560,000 people. MI’s during 1998 were identified from the 
Hospitals Information Department and confirmed by case 
note review. This research was approved by the Local Re-
search Ethics Committee. 
2.2  Follow-up 
The case records of all patients were reviewed to identify 
use of loop diuretics and if so whether this was due to 
symptoms or signs of HF. Follow-up data were collected 
until 31st December 2005. The occurrence of major events, 
such as recurrent MI, and stroke were recorded. 
2 Torabi A, et al. Development of heart failure after myocardial infarction 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
2.3  Definition of myocardial infarction (MI) 
At least two of the following five criteria were used to 
confirm a diagnosis of MI: (1) prolonged cardiac chest pain; 
(2) increases in biomarkers (in 1998, usually creatinine 
kinase (CK) or CK-MB mass); (3) electrocardiographic 
changes of MI or new-onset left bundle branch block; (4) 
sudden unexpected death; and (5) autopsy evidence of MI. 
2.4  Definitions  
Heart failure was defined either as signs and symptoms 
consistent with that diagnosis (principally breathlessness 
and signs of fluid retention) resulting in treatment with loop 
diuretics. Use of loop diuretics for the treatment of hyper-
tension or renal failure was not included in the definition of 
HF. Criteria for left ventricular systolic dysfunction (LVSD) 
were left ventricular ejection fraction (LVEF) < 40% or a 
qualitative report of moderate or severe LVSD. Patients 
were categorised into three age groups: (1) < 65 years; (2) 
65–75 years and (3) > 75 years. 
2.5  Resolution of heart failure 
Consistent with European Society of Cardiology Guide-
lines,[6] resolution of heart failure was defined as the with-
drawal of diuretics without the recurrence of symptoms.  
2.6  Statistical analysis 
Data were entered into a Microsoft Access database and 
analysed using SPSS Inc., version 13.0 (UK, Ltd.). Key 
outcomes were the proportion of patients who died and 
all-cause mortality. Continuously distributed data are pre-
sented as median and inter-quartile range (IQR). Categorical 
data are presented as percentages. Groups of patients with 
and without HF were compared by the Chi-squared test. 
Kaplan-Meier (K-M) curves were generated to illustrate 
patients’ overall survival, and in subgroups. K-M curves 
were compared by the log-rank test on the appropriate de-
grees-of-freedom. Cox regression was used to look at mor-
tality, from which hazard ratios (HRs) and 95%CIs were 
calculated. The Cox regression model is semi-parametric in 
the sense that no assumption concerning event-free survival 
times is necessary. The Cox regression model is based on 
the assumption that the effect of a risk factor, expressed as a 
HR, is constant over time. The assumption of proportional-
ity of the Cox model covariates was tested by plotting re-
siduals.[7,8] Linearity of continuous data was checked by 
including a squared term. We did not build a model using 
automated selection methods but rather on biological vari-
ables relevant to heart failure.[9] Hence, we adopted an epi-
demiological approach to model building. 
Heart failure status was categorised into six groups: (1) 
no HF at any time (this was the reference group for statisti-
cal comparisons); (2) persistent HF (PHF), patients with HF 
on the index admission and persisting at follow up until 
death or end of follow-up; (3) late resolution HF (LRHF),  
patients with HF on the index admission that resolved only 
subsequent to discharge; (4) recurrent HF (RHF), patients 
with HF on the index admission that resolved prior to dis-
charge but recurred during follow-up; (5) transient HF (THF) 
on the index admission that resolved prior to discharge and 
did not recur prior to death or end of follow-up; and (6) 
late-onset HF (LOHF), patients who did not develop HF on 
the index admission but who later developed HF during 
follow-up. 
3  Results 
Of 1,012 patients with a death or discharge diagnosis of 
acute MI in 1998, 116 were excluded from further analysis 
because they were transferred from another region or be-
cause MI could not be confirmed. This left 896 patients for 
analysis, of whom 311 (35%) were < 65 years, 297 (33%) 
65–75 years and 288 (32%) were > 75 years (Table 1). Sur-
vival status was known for all patients by December 2005, 
apart from 16, 8 and 6 from each age-group, respectively. 
About one third of patients were women. Older patients 
were less likely to be managed primarily by a cardiologist. 
ST-segment elevation myocardial infarction (STEMI) oc-
curred in 193 (62%), 174 (59%) and 151 (53%) cases. 
About 15% had a history of HF preceding the index event, 
rising from 7% in those aged < 65 years to 25% in those 
aged > 75 years.  
During the index admission, younger patients were more 
often treated with aspirin, statins, beta-blockers, intravenous 
nitrate, heparin and thrombolysis. Older patients were more 
likely to receive loop diuretic and digoxin (P < 0.001) (Ta-
ble 1). Primary angioplasty was not done in this hospital 
group in 1998.  
Overall, 75 (24%) patients < 65 years, 170 (57%) aged 
65–75 years, and 235 (82%) > 75 years had died by Decem-
ber 2005 (Figure 1). Figure 2 shows the overall proportion 
of patients that developed HF at any time during follow-up 
and their categorisation according to persistence, remission 
and timing of development of HF in different age groups.  
During the index hospitalization, 24 patients (8%) < 65 
years, 68 (23%) patients 65–75 years, 107 patients (37%) > 
75 years died with about 80% of deaths being associated 
with evidence of heart failure. Transient heart failure was 
observed in 26 (32%) patients < 65 years, in 27 (19%) pa-
tients 65–75 years, and in 21 (11%) patients > 75 years, but 
had resolved by discharge with cessation of diuretic therapy.   
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Table 1.  Patients characteristics recorded during the index admission overall and treatment during index admission and any time 
and classified according to the three different age group: > 65 yrs, 65–75 yrs and > 75 yrs (Data are Median (inter-quartile range) 
and n (%)). 
Variables Missing data All < 65 yrs 65–75 yrs > 75 yrs P value
N  896 311 (35%) 297 (33%) 288 (32%)  
Age (yrs) 0 70 (61–78) 58 (51–61) 71 (68–73) 81 (78–85) < 0.001
Women 0 333 (37%) 66 (21%) 120 (40%) 147 (51%) < 0.001
Current smoker 87 303 (37%) 166 (55%) 97 (35%) 40 (17%) < 0.001
Ex smoker  255 (32%) 85 (30%) 96 (35%) 74 (32%)  
History of hypertension 40 300 (35%) 81 (27%) 105 (37%) 114 (42%) < 0.001
History of diabetes 3 82+33a (13%) 33 (11%) 45 (15%) 37 (13%) 0.290 
Prior MI 1 235 (26%) 73 (24%) 73 (25%) 89 (31%) 0.153 
History of HF 4 134 (15%) 22 (7%) 39 (13%) 73 (25%) < 0.001
Prior CABG  39 (4%) 19 (6%) 14 (5%) 6 (2%) 0.051 
Prior PTCA  14 (2%) 10 (3%) 4 (1%) 0 < 0.001
Managed primarily by cardiologist  558 (62%) 233 (75%) 186 (63%) 139 (48%) < 0.001
Index admission ECG       
ST segment elevationb 10 518 (58%) 193 (62%) 174 (59%) 151 (53%) < 0.001
Chest X-ray       
Pulmonary oedema 227 160 (24%) 33 (14%) 54 (24%) 73 (33%) < 0.001
Physical examination       
Heart rate 9 78 (64–97) 73 (61–88) 76 (64–98) 85 (68–101) < 0.001
Atrial fibrillation (yes/no) 2 153 (17%) 19 (6%) 56 (19%) 78 (27%) < 0.001
Systolic blood pressure 5 140 (120–160) 132 (121–142) 140 (120–160) 140 (120–160) 0.610 
Blood tests (on admission)       
Peak CK 49 828 (376–1901) 1062 (418–2262) 767 (369–1779) 684 (318–1651) 0.018 
Creatinine 127 105 (89–129) 95 (83–108) 108 (90-132) 117 (96–149) < 0.001
Anaemia in 1st available Hbe 41 206 (24%) 34 (11%) 67 (24%) 105 (38%) < 0.001
Revascularisation during admission       
Thrombolysis 0 372 159 (51%) 127 (43%) 86 (30%) < 0.001
PCI 0 20 16 (0.05%) 4 (0.01%) 0(%) < 0.001
CABG 0 8 4 (0.01%) 3 (0.01%) 1 (0%) 0.459 
Treatment at any time during admission       
Selected parenteral agents       
Loop diuretic 7 262 49 (16%) 91 (31%) 122 (42%) < 0.001
Nitrates 3 309 125 (40%) 103 (35%) 81 (28%) 0.019 
Inotropic therapy 2 94 22 (0.07%) 34 (11%) 38 (13%) 0.121 
Oral       
Aspirin 2 792 302 (97%) 251 (85%) 239 (83%) < 0.001
Statin 2 406 214 (69%) 141 (48%) 51 (18%) < 0.001
ACE inhibitors 2 354 126 (41%) 120 (41%) 108 (38%) 0.782 
ARBs 2 8 2 (1%) 2 (1%) 4 (1%) 0.689 
Beta-blockers 2 497 236 (76%) 163 (55%) 98 (34%) < 0.001
Loop diuretic 3 297 58 (19%) 94 (32%) 145 (50%) < 0.001
Digoxin 2 68 6 (2%) 22 (7%) 40 (14%) < 0.001
Revascularisation at any timec       
PCI 0 94 72 (23%) 20 (8%) 2 (1%) < 0.001
CABG 0 98 58 (19%) 35 (12%) 5 (2%) < 0.001
To be contin. 
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Table 1. Contin. 
Variables Missing data All < 65 yrs 65–75 yrs > 75 yrs P value
Treatments at any timec       
ACE-inhibitors (seven cases prior to index were on ACE-inhibitors) 2 496 197 (63%) 170 (57%) 129 (45%) < 0.001
ARBs 2 44 26 (8%) 11 (4%) 7 (2%) < 0.001
Beta-blockers 2 541 256 (82%) 173 (58%) 99 (35%) < 0.001
Loop diuretic 2 539 130 (42%) 187 (63%) 222 (77%) < 0.001
Thiazide diuretic 2 68 30 (10%) 20 (8%) 18 (6%) 0.287 
Spironolactone 2 64 28 (9%) 20 (8%) 17 (6%) 0.301 
Digoxin 2 110 16 (5%) 38 (13%) 56 (20%) < 0.001
Insulin 1 92 33 (11%) 39 (13%) 20 (7%) 0.083 
Oral hypoglycaemic agent 2 67 26 (8%) 24 (8%) 17 (6%) 0.499 
Aspirin 2 805 304 (98%) 256 (86%) 245 (85%) < 0.001
Statin 2 530 269 (86%) 189 (64%) 72 (25%) < 0.001
Imagingd       
N  861 296 284 281  
Echocardiography  283 96 100 87  
Major LVSD 4 141 44 (46%) 51 (51%) 46 (55%) 0.029 
Moderate or severe mitral regurgitation 12 39 9 (9%) 14 (14%) 16 (18%) 0.519 
Moderate or severe other valve disease 6 11 1 (1%) 5 (5%) 5 (6%) 0.329 
Radionuclide  357 176 123 58  
LVEF 35%–40%  42 46 (26%) 39 (32%) 25 (43%) 0.087 
LVEF < 35%  110 18 (10%) 18 (15%) 6 (10%)  
Major LVSD/Survived and did not develop HFe  38 20 (20%) 11 (11%) 7 (9%)  
No major LVSD/Survived and did not develop HFf  142 92 (67%) 44 (45%) 6 (17%)  
No LV function report/Survived and did not develop HFg  44 26 (53%) 13 (16%) 5 (3%)  
Percentages are shown are of those in whom measurements were made. Example interpretation: older patients had high creatinie levels compare to younger patients. 
Many of these associations show dose-response. The differences for Na are exaggerated because of the relative large sample sizes between the three groups, and the 
relatively low standard deviations (in other words, this is a statistical quirk). aThirty-three cases newly diagnosed as diabetic on index admission; bP-value for ST cal-
culated between three groups (STE, No STE and other (LBBB) and pace); cTreatment any time until 31st December 2005; dEvidence of left ventricular function dur-
ing index admission or shortly after; eThree patients age < 65 years and one 65–75 years lost follow-up; fEight patients age < 65 years, two with 65–75 years and 
two in those > 75 years lost follow-up; gThree patients age < 65 years, two with 65–75 years lost follow-up. ARB: angiotensin receptor blockers; CABG: coronary 
artery bypass grafting; CK: creatine kinase; ECG: electrocardiogram; HF: heart failure; LBBB: Left bundle branch block; LVEF: left ventricular ejection fraction; 
LVSD: left ventricular systolic dysfunction; MI: myocardial infarction; STE: ST- segment elevation; PTCA: percutaneous transluminal coronary angioplasty. 
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Figure 1.  The sequence of events leading to the development of HF and/or death. (A): Flow diagram showing the sequence of devel-
opment of HF and relationship with recurrent ischemic episodes and mortality over approximately 6 years in patients less than 65 years old 
which admitted with an acute MI during 1998. Follow-up data were incomplete in 16 patients. (B): Flow diagram showing the sequence of 
development of heart failure and relationship with recurrent ischemic episodes and mortality over approximately 6 years in patients 65–75 
years old which admitted with an acute MI during 1998. Follow-up data were incomplete in 8 patients. (C): The sequence of development of 
heart failure and relationship with recurrent ischemic episodes and mortality over approximately 6 years in patients more than 75 years old 
which admitted with an acute MI during 1998. Follow-up data were incomplete in 6 patients. HF: heart failure; MI: myocardial infarction. 
Heart failure was present at discharge in 37 (12%) patients < 
65 years, 63 (21%) patients 65–75 years and 82 (28%) pa-
tients > 75 years, which had preceded admission in ap-
proximately one third of cases in each age group.  
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Figure 2.  The proportions of patients developing different categories of heart failure according to early mortality, timing of onset 
and persistence according to different age group. (A): > 65 years; (B): 65–75 years and (C): > 75 years. See methods for definitions of 
transient, persistent, remission and recurrence. HF: heart failure; MI: myocardial infarction; THF: transient heart failure. 
3.1  Long-term follow-up 
Amongst patients aged < 65 years, 65–75 years and > 75 
years with persistent heart failure at discharge, crude mor-
talities at six years were 41%, 70% and 76%, respectively. 
Amongst patients with transient heart failure during the in-
dex admission, it recurred in 46%, 56% and 67% and of 
these 23%, 56% and 81% died in each age group, respec-
tively. Amongst patients who did not have heart failure at 
discharge, 25%, 41% and 50% subsequently developed HF 
and of these 26%, 62% and 76% died in each age group, 
respectively. Thus of 271, 221 and 175 patients aged < 65 
years, 65–75 years and > 75 years who survived to dis-
charge and were not lost to follow-up, 50 (18%), 102 (46%) 
and 126 (72%) subsequently died, of whom 35 (70%), 93 
(91%) and 107 (85%) first developed HF (Figures 3A, 3B).  
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A report on LV function during or shortly after the index 
admission was available in 228 (83%), 175 (81%) and 104 
(60%) surviving patients in the three age groups and in 16, 
24 and 31 patients who died during the index admission 
(Table 1). LVSD was associated with a greater likelihood of 
developing heart failure and a worse prognosis. 
Of patients who died after the index admission, 23 (45%), 
67 (66%) and 78 (61%) patients died during a re-admission 
to hospital in each of the three age groups (Table 2). Little 
detailed information was available for out-of-hospital deaths 
but review of existing data suggested that most were unex-
pected and probably sudden. 
3.2  Cox model 
Patients with HF during the index admission had the 
poorest survival across all age groups (Figure 3A and B) 
particularly if PHF. The increased risk conferred by PHF 
was marked for patients aged 65–75 years and less pro-
nounced for patients aged > 75 years, most of whom devel-
oped HF and had a poor outcome even if they were not re-
ported to develop HF (Table 3). 
 
 
Figure 3.  The prognosis of patients discharged after the index MI according to different age groups with and without any HF. (A): 
Prognosis amongst patients discharged after the index myocardial infarction in different age groups (> 65 years, 65–75 years and > 75 years) 
with any HF (persistent or transient) and those who never developed HF; (B): Kaplan-Meier curves showing prognosis amongst patients 
discharged after the index myocardial infarction with and without transient or persistent heart failure according to different age group (> 65 
years, 65–75 years and > 75 years). For statistical comparisons see Table 3. HF: heart failure; MI: myocardial infarction. 
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Table 2.  Mode of death in patients who died during index admission (n = 199) and subsequent to discharge (n = 281). 
 All Age < 65 years Age 65–75 years Age > 75 years 
 896 311 (35%) 297 (33%) 288 (32%) 
Died during index admission 199 24 68 107 
   SCD 55 6 18 31 
   HF 114 16 38 60 
   Stroke 2 0 0 2 
   Cardiac procedures related 4 0 1 3 
   Other cardiac 8 1 3 4 
   Infection 4 0 2 2 
   Cancer 1 0 0 1 
   Other non cardiac 11 1 6 4 
Died after the index admission 281 51 102 128 
Died during a re-admission 168a 23 67 78 
   SCD 9 2 3 4 
   HF 68 8 (35%) 30 (45%) 30 (39%) 
   Stroke 11 1 4 6 
   Cardiac procedures related 2 0 2 0 
   Other cardiac 4 1 1 2 
   Infection 22 2 7 13 
   Cancer 24 6 8 10 
   Other non cardiac 27 3 12 12 
Died out of hospitalb 113 28 35 50 
   Severe HFc 16 7 5 4 
   Advanced cancer 9 2 2 5 
   Stroke 2 1 0 1 
Any transient or persistent HF 83 17 29 37 
   Any HF with LVSD prior to deathd 48 12 20 16 
   Any HF with no LV assessment  16 2 3 11 
   Any HF with No LVSD 19 3 6 10 
Never HF  30 11 6 13 
   Never HF with LVSD prior to death 7 5 2 0 
   Never HF with no LV assessment  10 2 2 6 
   Any HF with No LVSD 13 4 2 7 
aOne patient with age > 75 years had missing data during last admission; bwith age 65–75 years one patients died of self-poisoning, with age < 65 
years one patient had three vessel disease and was waiting for CABG, one patient had three vessel disease and was waiting for PTCA and another had 
LAD disease but were not suitable for surgery and one patient 65–75 year old had severe pulmonary hypertension; cSevere HF during one month 
prior to death of whom two had missed HF (chest X-rays report were pulmonary oedema after death); dLVSD in last cardiac imaging prior to death 
P-values not calculated owing to small cell numbers. CABG: coronary artery bypass grafting; HF: heart failure; LAD: left anterior descending; LVSD: 
left ventricular systolic dysfunction; PTCA: percutaneous transluminal coronary angioplasty; SCD: Sudden cardiac death. 
 
4  Discussion 
This analysis shows that the development of heart failure 
after a MI increases steeply with age, that most patients who 
die subsequent to a MI will first develop heart failure and 
that heart failure is a powerful adverse prognostic factor. 
Patients aged < 65 years were least likely to get heart fail-
ure but half developed it over the subsequent six years and 
70% of deaths in this age group occurred subsequent to the 
onset of heart failure. For patients aged 65–75 years, 73% 
developed heart failure during follow-up and 91% of deaths   
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Table 3.  Cox-regression models, unadjusted and multivariate-adjusted procedures of mortality in patients subsequent to discharge 
(n = 667). 
 Univariate  Multivariable adjusted 
Variable n 
 HR P value  HR P value 
< 65 years old 271       
Heart failure status* 156 30.559   24.632   
    PHF-persistent at follow up 28 26.103 6.701 (3.230–13.902) < .001 20.904 5.889 (2.754–12.593) < 0.001 
    PHF-resolved at follow up 9 0.618 0.450 (0.061–3.301) 0.432 0.436 0.507 (0.068–3.802) 0.509 
    THF-redevelop HF  12 2.667 2.543 (0.830–7.793) 0.102 2.378 2.420 (0.787–7.439) 0.123 
    THF-remission at follow up 13 1.203 0.319 ( 0.042–2.456) 0.273 1.160 0.326 (0.042–2.508) 0.281 
    No HF-developed HF 53 1.035 1.512 (0.682–3.351) 0.309 0.915 1.478 (0.664–3.287) 0.339 
Re-admission with MI 39 9.474 2.638 (1.422–4.893) < .001 2.607 1.747 (0.888–3.437) < 0.106 
Re-admission with angina 51 0.019 0.950 (0.462–1.955) 0.890 0.027 0.938 (0.435–2.022) < 0.870 
65–75 years old 221       
Heart failure status* 79 49.172   46.855   
    PHF-persistent at follow up 56 44.738 11.798 (5.724–24.315) < .001 42.600 11.408 (5.492–23.697) < 0.001 
    PHF-resolved at follow up  5 0.136 1.309 (0.313–5.483) 0.712 0.225 1.416 (0.337–5.960) 0.635 
    THF-redevelop HF  15 6.317 2.683 (1.243–5.791) 0.012 4.199 2.143 (1.036–4.856) 0.040 
    THF-remission at follow up 11 0.796 0.578 (0.173–1.929) 0.372 1.089 0.526 (0.157–1.758) 0.297 
    No HF-developed HF 55 4.398 1.753 (1.037–2.962) 0.036 2.433 1.525 (0.897–2.592) 0.119 
Re-admission with MI 47 21.711 2.660 (1.763–4.015) < .001 3.718 1.522 (0.993–2.334) 0.054 
Re-admission with angina 39 11.348 0.267 (0.124–0.576) < .001 8.644 0.305 (0.138-0.673) < .001 
> 75 years old 175       
Heart failure status* 37 14.914   12.452   
    PHF-persistent at follow up 72 11.415 2.452 (1.457–4.127) < .001 7.580 2.114 (1.241–3.603) < 0.001 
    PHF-resolved at follow up  8 1.572 0.523 (0.190–1.441) 0.210 2.580 0.434 (0.157–1.202) 0.108 
    THF-redeveloped HF  14 3.293 1.872 (0.951–3.684) 0.070 3.266 1.869 (0.948–3.682) 0.071 
    THF-remission at follow up 7 0.463 1.381 (0.545–3.504) 0.496 1.184 1.689 (0.657–4.338) 0.277 
    No HF-developed HF 37 0.335 1.152 (0.713–1.861) 0.563 0.328 1.151 (0.711–1.863) 0.567 
Re-admission with MI 59 7.351 1.641 (1.147–2.349) < .001 1.516 1.269 (0.868–1.855) 0.218 
Re-admission with angina 21 9.641 0.321 (0.157–0.658) < .001 7.531 0.357 (0.171–0.745) < 0.001 
*With reference to No HF any time (index admission and follow up). HF: heart failure; HR: hazard ratio; MI: myocardial infarction; PHF: persistent heart 
failure during the index admission; THF: transient HF during the index admission. 
 
in this group occurred subsequent to the development of 
HF. In patients aged > 75 years, 87% developed heart fail-
ure but the prognosis was poor whether or not overt heart 
failure developed. Few of those with documented substan-
tial LVSD after a myocardial infarction escaped death or 
the development of heart failure over the subsequent six 
years. However, about half of patients in whom substantial 
LVSD had been excluded still went on to develop heart 
failure, of whom a large proportion died. Thus the preven-
tion and management of heart failure rather than LVSD 
may be the most important therapeutic target in patients 
with heart failure. 
This cohort of patients was enrolled prior to the wide-
spread adoption of primary angioplasty and before national 
audits were introduced to improve the quality of care. 
Treatments to restore coronary perfusion were suboptimal. 
Studies show that thrombolysis and primary percutaneous 
angioplasty can reduce myocardial damage[10–12] leading to 
improved long-term recovery of cardiac function[13–15] and 
reduced mortality.[16–19] This should reduce the incidence of 
heart failure, although evidence in support of this hypothesis 
is scant. ACE inhibitors,[20] angiotensin receptor block-
ers,[21,22] aldosterone receptor antagonists,[23] beta-blockers[24] 
and statins[25] were not used optimally by contemporary 
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standards. Greater use might have assisted recovery in ven-
tricular function, reduced the development of heart failure 
and improved prognosis. Thus, our data should not be per-
ceived as an accurate description of outcome in contempo-
rary patients but rather likely outcome if modern standards 
are not applied. Further cohorts should be enrolled to assess  
contemporary populations, recognising these must still be 
many years out of date if 5-year outcome is to be reported. 
Great care should be taken in case-ascertainment. Those 
lucky enough to reach the catheter laboratory probably have 
a better prognosis than those who do not, partly due to 
case-selection. 
Hopefully, improvements in care have improved the 
prognosis of patients with myocardial infarction.[26] How-
ever, a repeat survey in our hospital conducted in 2005, with 
much higher uptake of guideline-indicated therapy, revealed 
a three year mortality which was still in excess of 30%, 
suggesting that the prognosis of MI in epidemiologically 
representative cohorts of patients, not just those who get to 
the catheter laboratory, remains poor.[27] Overall, our cohort 
of patients was most unlike that observed in clinical trials. 
The median age in our cohort in 1998 was 70 years and 
35% were women.[1] This had changed little by 2005 and is 
similar to that reported by the Myocardial Infarction Na-
tional Audit Programme (MINAP) in the UK in 2003–2005 
(mean age 69 years and 36% women).[28] The Euro Heart 
Survey of Acute Coronary Syndromes reported a mean age 
of just 63 years and 29% women amongst patients with an 
ST elevation MI and 66 years and 36% in those with MI but 
no ST elevation.[29] In contemporary clinical trials of acute 
MI, such as the Platelet Inhibition and Patient Outcomes 
(PLATO) study, the median age was only 62 years, only 
15% were ≥ 75 years old and 28% were women.[30] One 
year mortality, including in-patient deaths, was only 6%. 
The mean age of these patients was 61 years and only 11% 
were aged ≥ 75 years.[31] In the TRITON-TIMI 38 study, the 
median age was 61 years and only 13% of patients were 
aged > 75 years.[32] Overall mortality was 3% over a median 
follow-up of 15 months, patients aged > 75 years were more 
likely to reach the primary end-point (cardiovascular death, 
MI or stroke) (18.3% vs. 10.6% in those assigned to clopi-
dogrel). These outcomes compare to in-patient and one year 
mortalities in our epidemiological cohorts of 22% and 31% 
in 1998 and 11% and 19% in 2005.[1,27] The difference in 
outcome between observational and trial data-sets could 
reflect differences in care but may also reflect differences in 
case ascertainment and selection. Old, frail patients with 
multiple comorbidities may be excluded by the protocol or 
may decline to participate in trials. Alternatively, investiga-
tors, for a variety of reasons including compassion and the 
fact that managing such cases consumes more research time 
and resources, may avoid enrolling frail, elderly patients. A 
low threshold for the detection of MI with the use of more 
sensitive troponin assays may also lead to an apparent im-
provement in prognosis, as small MIs will generally have a 
better prognosis than large ones. The quality of care may 
also be inferior in older patients. However, it is also possible 
that compassionate clinicians decide that palliative care is 
appropriate and that it is no longer appropriate to try to 
modify the prognosis in some older patients. The rights and 
wrongs must be argued on an individual case basis.  
The prognosis of younger patients enrolled in many con-
temporary trials of acute coronary syndrome is now so good 
it may be difficult to improve. Clinical trials specifically 
amongst older patients would be valuable as they are at high 
risk, both in terms of prognosis and side effects of treatment. 
The balance of risk and benefit may differ from younger 
patients.[33,34] However, disease in older patients may be 
more resistant to modification by therapy. 
The problem may not be so much chronological as bio-
logical age. Older patients have more co-morbid conditions 
such as AF, conducting system disease, respiratory disease, 
renal dysfunction, anaemia and, worst of all, heart failure. In 
a sense, age is a surrogate for the drivers of an adverse out-
come. Identification and effective management of these 
co-morbidities might improve outcomes. Patients aged 
65–75 years are at intermediate risk and this may be where 
the greatest therapeutic gains occur. It may be difficult to 
reduce risk in a group already at low risk, whereas in pa-
tients aged > 75 years, an effective therapy may still not be 
effective enough to make a meaningful difference in out-
come.[35] Identifying and managing modifiable risk is key 
and it may be best to target intermediate risk to achieve the 
greatest benefit. 
4.1  Study limitations 
Substantial changes in management have occurred since 
1998 as discussed above. Systematic attempts were not 
made to withdraw diuretics, therefore we may have over- 
estimated the persistence of HF. A simple, robust definition 
of HF remains elusive. However, patients who receive loop 
diuretics and who have cardiovascular disease clearly have a 
poor prognosis whether or not they have a low ejection frac-
tion.[36] Ultimately, the diagnosis of HF relies on a doctor’s 
skill in assessing patients in the light of appropriate investi-
gations. It is probably under- rather than over-diagnosed. 
4.2  Conclusions 
The development of HF precedes death in the great ma-
jority of patients who die within six years of an MI, espe-
Torabi A, et al. Development of heart failure after myocardial infarction 11 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
cially amongst patients aged > 65 years. Improved preven-
tion and management of HF and its important co-morbidi-
ties may improve outcome.  
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